
Opinion|Videos|June 2, 2025
Considerations for Ruxolitinib Therapy in Steroid-Refractory cGVHD
Panelists discuss how clinicians typically taper steroids slowly after starting second-line agents for chronic graft-vs-host disease (cGVHD).
Advertisement
Episodes in this series

Steroid Tapering with Second-Line Therapy
This detailed segment covers approaches to steroid tapering when initiating second-line therapy. The panelists agree on:
- Waiting 3-4 weeks after starting a new agent (like ruxolitinib) before beginning steroid taper
- Prioritizing steroid discontinuation before tapering other agents
- Tapering steroids by approximately 10mg every 4 weeks, slowing the taper at lower doses
- Very gradual tapering of ruxolitinib once steroids are discontinued, sometimes using alternate-day dosing
Dr Lee notes that at Fred Hutchinson Cancer Center, they taper ruxolitinib more slowly than the prescribing information recommends, sometimes tapering to 5 mg several days per week before complete discontinuation.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Tarlatamab Plus Durvalumab Improves Survival in First-Line ES-SCLC
2
AUA/SUO Issue 2026 Update to Non–Muscle-Invasive Bladder Cancer Guideline
3
Dr Pant Discusses Next Steps in Daraxonrasib Development for Pancreatic Cancer
4
FDA Approves Camizestrant Plus CDK4/6 Inhibitor for ESR1-Mutant Breast Cancer
5



































